Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis-Reference-Cited by-同舟云学术

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis

Published:2017-07-05 Issue:1 Volume:179 Page:83-97
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Leitch Heather A.¹^ORCID,Parmar Ambica²,Wells Richard A.³,Chodirker Lisa³,Zhu Nancy⁴,Nevill Thomas J.⁵,Yee Karen W. L.⁶,Leber Brian⁷,Keating Mary-Margaret⁸,Sabloff Mitchell⁹,St. Hilaire Eve¹⁰,Kumar Rajat¹¹,Delage Robert¹²,Geddes Michelle¹³,Storring John M.¹⁴,Kew Andrea⁸,Shamy April¹⁵,Elemary Mohamed¹⁶,Lenis Martha³,Mamedov Alexandre³,Ivo Jessica³,Francis Janika³,Zhang Liying³,Buckstein Rena³^ORCID

Affiliation:

1. Hematology; St. Paul's Hospital and the University of British Columbia; Vancouver BC Canada

2. University of Toronto; Toronto ON Canada

3. Odette Cancer Centre; Sunnybrook Health Sciences Centre; Toronto ON Canada

4. Hematology/Oncology; University of Alberta; Edmonton AB Canada

5. Division of Hematology; Leukemia/BMT Program of British Columbia; Vancouver BC Canada

6. Princess Margaret Cancer Centre; University Health Network; Toronto ON Canada

7. McMaster University; Hamilton ON Canada

8. Queen Elizabeth II Health Sciences Center; Halifax NS Canada

9. Ottawa General Hospital; Ottawa ON Canada

10. Centre d'Oncologie, Dr-Leon-Richard; Moncton NB Canada

11. Hematology/Oncology; CancerCare Manitoba; Winnipeg MB Canada

12. Hematology Department; Centre Hospitalier Universitaire; Laval University; Quebec QC Canada

13. Department of Medicine/Hematology; Foothills Medical Centre; Calgary AB Canada

14. McGill University Health Center; Montreal QC Canada

15. Sir Mortimer B Davis Hospital; McGill University; Montreal QC Canada

16. Saskatoon Cancer Center; University of Saskatchewan; Saskatoon SK Canada

Funder

Novartis Canada Corporation

Canadian Institute for Health Research

Celgene

Crashley Estate

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14825/fullpdf

Reference64 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;Journal of the National Cancer Institute,1993

2. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology;Alessandrino;Haematologica,2002

3. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 trial);Angelucci;European Journal of Haematology,2014

4. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life;Balducci;Cancer,2006

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of reactive oxygen species in myelodysplastic syndromes;Cellular & Molecular Biology Letters;2024-04-14

2. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia;Haematologica;2024-02-01

3. Transfusions et chélation du fer dans les syndromes myélodysplasiques;Bulletin du Cancer;2023-11

4. Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-08

5. The Management of Low-Risk Myelodysplastic Syndromes—Current Standards and Recent Advances;The Cancer Journal;2023-05